#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Discussion
1-1	0-2	3.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Synthetic lethality has immense potential in cancer therapeutics .
2-1	14-23	Synthetic	abstract[2]	new[2]	coref	4-12[0_2]
2-2	24-33	lethality	abstract[2]	new[2]	_	_
2-3	34-37	has	_	_	_	_
2-4	38-45	immense	abstract[3]	new[3]	_	_
2-5	46-55	potential	abstract[3]	new[3]	_	_
2-6	56-58	in	_	_	_	_
2-7	59-65	cancer	abstract|abstract[5]	new|new[5]	coref	5-24
2-8	66-78	therapeutics	abstract[5]	new[5]	_	_
2-9	79-80	.	_	_	_	_

#Text=Where the driver genes or oncogenes cannot be targeted , synthetic lethal interactors can potentially serve as drug targets in the presence of mutations in the driver genes , as the mutant tumor cells are dependent upon the synthetic lethal interactors for their survival .
3-1	81-86	Where	_	_	_	_
3-2	87-90	the	abstract[6]	new[6]	coref	3-26[14_6]
3-3	91-97	driver	abstract[6]	new[6]	_	_
3-4	98-103	genes	abstract[6]	new[6]	_	_
3-5	104-106	or	_	_	_	_
3-6	107-116	oncogenes	substance	new	_	_
3-7	117-123	cannot	_	_	_	_
3-8	124-126	be	_	_	_	_
3-9	127-135	targeted	_	_	_	_
3-10	136-137	,	_	_	_	_
3-11	138-147	synthetic	event[8]	new[8]	coref	3-38[17_8]
3-12	148-154	lethal	event[8]	new[8]	_	_
3-13	155-166	interactors	event[8]	new[8]	_	_
3-14	167-170	can	_	_	_	_
3-15	171-182	potentially	_	_	_	_
3-16	183-188	serve	_	_	_	_
3-17	189-191	as	_	_	_	_
3-18	192-196	drug	substance|abstract[10]	new|new[10]	coref|coref	5-20|6-18[46_10]
3-19	197-204	targets	abstract[10]	new[10]	_	_
3-20	205-207	in	_	_	_	_
3-21	208-211	the	abstract[11]	new[11]	_	_
3-22	212-220	presence	abstract[11]	new[11]	_	_
3-23	221-223	of	abstract[11]	new[11]	_	_
3-24	224-233	mutations	abstract[11]|abstract[12]	new[11]|new[12]	coref	14-11[133_12]
3-25	234-236	in	abstract[11]|abstract[12]	new[11]|new[12]	_	_
3-26	237-240	the	abstract[11]|abstract[12]|abstract[14]	new[11]|new[12]|giv[14]	coref	4-15[26_14]
3-27	241-247	driver	abstract[11]|abstract[12]|person|abstract[14]	new[11]|new[12]|new|giv[14]	_	_
3-28	248-253	genes	abstract[11]|abstract[12]|abstract[14]	new[11]|new[12]|giv[14]	_	_
3-29	254-255	,	_	_	_	_
3-30	256-258	as	_	_	_	_
3-31	259-262	the	animal[16]	new[16]	ana	3-43[0_16]
3-32	263-269	mutant	animal[16]	new[16]	_	_
3-33	270-275	tumor	abstract|animal[16]	new|new[16]	coref	7-47
3-34	276-281	cells	animal[16]	new[16]	_	_
3-35	282-285	are	_	_	_	_
3-36	286-295	dependent	_	_	_	_
3-37	296-300	upon	_	_	_	_
3-38	301-304	the	event[17]	giv[17]	coref	8-11[71_17]
3-39	305-314	synthetic	event[17]	giv[17]	_	_
3-40	315-321	lethal	event[17]	giv[17]	_	_
3-41	322-333	interactors	event[17]	giv[17]	_	_
3-42	334-337	for	_	_	_	_
3-43	338-343	their	animal|event[19]	giv|new[19]	coref	18-21[180_0]
3-44	344-352	survival	event[19]	new[19]	_	_
3-45	353-354	.	_	_	_	_

#Text=Recent advances in RNAi and CRISPR technologies have enabled large-scale synthetic lethality screens for individual genes to be performed in human cell lines .
4-1	355-361	Recent	abstract[20]	new[20]	_	_
4-2	362-370	advances	abstract[20]	new[20]	_	_
4-3	371-373	in	abstract[20]	new[20]	_	_
4-4	374-378	RNAi	abstract[20]|abstract|abstract[23]	new[20]|new|new[23]	_	_
4-5	379-382	and	abstract[20]|abstract[23]	new[20]|new[23]	_	_
4-6	383-389	CRISPR	abstract[20]|place|abstract[23]	new[20]|new|new[23]	_	_
4-7	390-402	technologies	abstract[20]|abstract[23]	new[20]|new[23]	_	_
4-8	403-407	have	_	_	_	_
4-9	408-415	enabled	_	_	_	_
4-10	416-427	large-scale	abstract[25]	new[25]	coref	7-23[62_25]
4-11	428-437	synthetic	abstract[25]	new[25]	_	_
4-12	438-447	lethality	abstract|abstract[25]	giv|new[25]	coref	11-12[102_0]
4-13	448-455	screens	abstract[25]	new[25]	_	_
4-14	456-459	for	abstract[25]	new[25]	_	_
4-15	460-470	individual	abstract[25]|abstract[26]	new[25]|giv[26]	coref	8-15[73_26]
4-16	471-476	genes	abstract[25]|abstract[26]	new[25]|giv[26]	_	_
4-17	477-479	to	_	_	_	_
4-18	480-482	be	_	_	_	_
4-19	483-492	performed	_	_	_	_
4-20	493-495	in	_	_	_	_
4-21	496-501	human	object[28]	new[28]	coref	5-24[40_28]
4-22	502-506	cell	place|object[28]	new|new[28]	coref	5-25
4-23	507-512	lines	object[28]	new[28]	_	_
4-24	513-514	.	_	_	_	_

#Text=The genetic dependency map ( DepMap ) project is dedicated towards finding genetic dependencies from the published shRNA/CRISPR or drug screening data in cancer cell lines .
5-1	515-518	The	abstract[32]	new[32]	_	_
5-2	519-526	genetic	abstract[29]|abstract[30]|abstract[32]	new[29]|new[30]|new[32]	appos	5-6[0_30]
5-3	527-537	dependency	abstract[29]|abstract[30]|abstract[32]	new[29]|new[30]|new[32]	_	_
5-4	538-541	map	abstract[30]|abstract[32]	new[30]|new[32]	_	_
5-5	542-543	(	abstract[32]	new[32]	_	_
5-6	544-550	DepMap	abstract|abstract[32]	giv|new[32]	_	_
5-7	551-552	)	abstract[32]	new[32]	_	_
5-8	553-560	project	abstract[32]	new[32]	_	_
5-9	561-563	is	_	_	_	_
5-10	564-573	dedicated	_	_	_	_
5-11	574-581	towards	_	_	_	_
5-12	582-589	finding	_	_	_	_
5-13	590-597	genetic	abstract[33]	new[33]	coref	6-3[41_33]
5-14	598-610	dependencies	abstract[33]	new[33]	_	_
5-15	611-615	from	_	_	_	_
5-16	616-619	the	abstract[34]	new[34]	_	_
5-17	620-629	published	abstract[34]	new[34]	_	_
5-18	630-642	shRNA/CRISPR	abstract[34]	new[34]	_	_
5-19	643-645	or	_	_	_	_
5-20	646-650	drug	substance|abstract[37]	giv|new[37]	coref|coref	7-46[68_37]|10-21
5-21	651-660	screening	event|abstract[37]	new|new[37]	coref	10-22
5-22	661-665	data	abstract[37]	new[37]	_	_
5-23	666-668	in	abstract[37]	new[37]	_	_
5-24	669-675	cancer	abstract[37]|abstract|object[40]	new[37]|giv|giv[40]	coref|coref	6-21|10-25[98_40]
5-25	676-680	cell	abstract[37]|place|object[40]	new[37]|giv|giv[40]	coref	10-26
5-26	681-686	lines	abstract[37]|object[40]	new[37]|giv[40]	_	_
5-27	687-688	.	_	_	_	_

#Text=While identifying genetic dependencies or essentiality in the context of specific genetic alterations is important for screening potential targets for cancer therapy , identification of clinically relevant synthetic lethal pairs in cancers has been a challenge .
6-1	689-694	While	_	_	_	_
6-2	695-706	identifying	_	_	_	_
6-3	707-714	genetic	abstract[41]|abstract[42]	giv[41]|giv[42]	coref	6-3[42_41]
6-4	715-727	dependencies	abstract[41]|abstract[42]	giv[41]|giv[42]	_	_
6-5	728-730	or	abstract[42]	giv[42]	_	_
6-6	731-743	essentiality	abstract[42]|abstract	giv[42]|new	_	_
6-7	744-746	in	_	_	_	_
6-8	747-750	the	abstract[44]	new[44]	_	_
6-9	751-758	context	abstract[44]	new[44]	_	_
6-10	759-761	of	abstract[44]	new[44]	_	_
6-11	762-770	specific	abstract[44]|abstract[45]	new[44]|new[45]	_	_
6-12	771-778	genetic	abstract[44]|abstract[45]	new[44]|new[45]	_	_
6-13	779-790	alterations	abstract[44]|abstract[45]	new[44]|new[45]	_	_
6-14	791-793	is	_	_	_	_
6-15	794-803	important	_	_	_	_
6-16	804-807	for	_	_	_	_
6-17	808-817	screening	_	_	_	_
6-18	818-827	potential	abstract[46]	giv[46]	coref	11-16[104_46]
6-19	828-835	targets	abstract[46]	giv[46]	_	_
6-20	836-839	for	abstract[46]	giv[46]	_	_
6-21	840-846	cancer	abstract[46]|abstract|abstract[48]	giv[46]|giv|new[48]	coref	8-16
6-22	847-854	therapy	abstract[46]|abstract[48]	giv[46]|new[48]	_	_
6-23	855-856	,	_	_	_	_
6-24	857-871	identification	abstract[49]	new[49]	coref	6-35[52_49]
6-25	872-874	of	abstract[49]	new[49]	_	_
6-26	875-885	clinically	abstract[49]|abstract[50]	new[49]|new[50]	_	_
6-27	886-894	relevant	abstract[49]|abstract[50]	new[49]|new[50]	_	_
6-28	895-904	synthetic	abstract[49]|abstract[50]	new[49]|new[50]	_	_
6-29	905-911	lethal	abstract[49]|abstract[50]	new[49]|new[50]	_	_
6-30	912-917	pairs	abstract[49]|abstract[50]	new[49]|new[50]	_	_
6-31	918-920	in	abstract[49]|abstract[50]	new[49]|new[50]	_	_
6-32	921-928	cancers	abstract[49]|abstract[50]|abstract	new[49]|new[50]|new	coref	20-10
6-33	929-932	has	_	_	_	_
6-34	933-937	been	_	_	_	_
6-35	938-939	a	abstract[52]	giv[52]	_	_
6-36	940-949	challenge	abstract[52]	giv[52]	_	_
6-37	950-951	.	_	_	_	_

#Text=A recent work tried to address this limitation with an in silico analysis of clinical relevance of the SL interactions identified from in vitro SL screens and reported that only a fraction of these SL interactions hold up to be clinically significant when tested on TCGA tumor data .
7-1	952-953	A	abstract[53]	new[53]	_	_
7-2	954-960	recent	abstract[53]	new[53]	_	_
7-3	961-965	work	abstract[53]	new[53]	_	_
7-4	966-971	tried	_	_	_	_
7-5	972-974	to	_	_	_	_
7-6	975-982	address	_	_	_	_
7-7	983-987	this	abstract[54]	new[54]	_	_
7-8	988-998	limitation	abstract[54]	new[54]	_	_
7-9	999-1003	with	_	_	_	_
7-10	1004-1006	an	abstract[56]	new[56]	_	_
7-11	1007-1009	in	place[55]|abstract[56]	new[55]|new[56]	coref	10-12[0_55]
7-12	1010-1016	silico	place[55]|abstract[56]	new[55]|new[56]	_	_
7-13	1017-1025	analysis	abstract[56]	new[56]	_	_
7-14	1026-1028	of	abstract[56]	new[56]	_	_
7-15	1029-1037	clinical	abstract[56]|abstract[57]	new[56]|new[57]	coref	9-30[84_57]
7-16	1038-1047	relevance	abstract[56]|abstract[57]	new[56]|new[57]	_	_
7-17	1048-1050	of	abstract[56]|abstract[57]	new[56]|new[57]	_	_
7-18	1051-1054	the	abstract[56]|abstract[57]|abstract[59]	new[56]|new[57]|new[59]	coref	7-34[65_59]
7-19	1055-1057	SL	abstract[56]|abstract[57]|abstract|abstract[59]	new[56]|new[57]|new|new[59]	coref	7-35
7-20	1058-1070	interactions	abstract[56]|abstract[57]|abstract[59]	new[56]|new[57]|new[59]	_	_
7-21	1071-1081	identified	abstract[56]|abstract[57]|abstract[59]	new[56]|new[57]|new[59]	_	_
7-22	1082-1086	from	abstract[56]|abstract[57]|abstract[59]	new[56]|new[57]|new[59]	_	_
7-23	1087-1089	in	abstract[56]|abstract[57]|abstract[59]|organization[60]|abstract[62]	new[56]|new[57]|new[59]|new[60]|giv[62]	coref|coref	8-4[69_60]|8-3[70_62]
7-24	1090-1095	vitro	abstract[56]|abstract[57]|abstract[59]|organization[60]|abstract[62]	new[56]|new[57]|new[59]|new[60]|giv[62]	_	_
7-25	1096-1098	SL	abstract[56]|abstract[57]|abstract[59]|person|abstract[62]	new[56]|new[57]|new[59]|new|giv[62]	_	_
7-26	1099-1106	screens	abstract[56]|abstract[57]|abstract[59]|abstract[62]	new[56]|new[57]|new[59]|giv[62]	_	_
7-27	1107-1110	and	_	_	_	_
7-28	1111-1119	reported	_	_	_	_
7-29	1120-1124	that	_	_	_	_
7-30	1125-1129	only	abstract[63]	new[63]	_	_
7-31	1130-1131	a	abstract[63]	new[63]	_	_
7-32	1132-1140	fraction	abstract[63]	new[63]	_	_
7-33	1141-1143	of	abstract[63]	new[63]	_	_
7-34	1144-1149	these	abstract[63]|abstract[65]	new[63]|giv[65]	coref	10-5[88_65]
7-35	1150-1152	SL	abstract[63]|abstract|abstract[65]	new[63]|giv|giv[65]	coref	10-5
7-36	1153-1165	interactions	abstract[63]|abstract[65]	new[63]|giv[65]	_	_
7-37	1166-1170	hold	_	_	_	_
7-38	1171-1173	up	_	_	_	_
7-39	1174-1176	to	_	_	_	_
7-40	1177-1179	be	_	_	_	_
7-41	1180-1190	clinically	_	_	_	_
7-42	1191-1202	significant	_	_	_	_
7-43	1203-1207	when	_	_	_	_
7-44	1208-1214	tested	_	_	_	_
7-45	1215-1217	on	_	_	_	_
7-46	1218-1222	TCGA	substance|abstract[68]	new|giv[68]	coref	9-16[0_68]
7-47	1223-1228	tumor	abstract|abstract[68]	giv|giv[68]	coref	19-15
7-48	1229-1233	data	abstract[68]	giv[68]	_	_
7-49	1234-1235	.	_	_	_	_

#Text=Also , these in vitro screens are costly and finding synthetic lethal interactors for many cancer genes remain challenging .
8-1	1236-1240	Also	_	_	_	_
8-2	1241-1242	,	_	_	_	_
8-3	1243-1248	these	abstract[70]	giv[70]	_	_
8-4	1249-1251	in	organization[69]|abstract[70]	giv[69]|giv[70]	_	_
8-5	1252-1257	vitro	organization[69]|abstract[70]	giv[69]|giv[70]	_	_
8-6	1258-1265	screens	abstract[70]	giv[70]	_	_
8-7	1266-1269	are	_	_	_	_
8-8	1270-1276	costly	_	_	_	_
8-9	1277-1280	and	_	_	_	_
8-10	1281-1288	finding	_	_	_	_
8-11	1289-1298	synthetic	event[71]	giv[71]	coref	17-12[172_71]
8-12	1299-1305	lethal	event[71]	giv[71]	_	_
8-13	1306-1317	interactors	event[71]	giv[71]	_	_
8-14	1318-1321	for	event[71]	giv[71]	_	_
8-15	1322-1326	many	event[71]|abstract[73]	giv[71]|giv[73]	coref	9-24[83_73]
8-16	1327-1333	cancer	event[71]|abstract|abstract[73]	giv[71]|giv|giv[73]	coref	9-14
8-17	1334-1339	genes	event[71]|abstract[73]	giv[71]|giv[73]	_	_
8-18	1340-1346	remain	_	_	_	_
8-19	1347-1358	challenging	_	_	_	_
8-20	1359-1360	.	_	_	_	_

#Text=SL-BioDP addresses such problems by using a computational method that leverages the available cancer genetic data resources to predict synthetic lethal partners of all cancer susceptibility genes and assesses the clinical relevance from matched clinical data .
9-1	1361-1369	SL-BioDP	abstract	new	coref	11-1
9-2	1370-1379	addresses	_	_	_	_
9-3	1380-1384	such	abstract[75]	new[75]	_	_
9-4	1385-1393	problems	abstract[75]	new[75]	_	_
9-5	1394-1396	by	_	_	_	_
9-6	1397-1402	using	_	_	_	_
9-7	1403-1404	a	abstract[76]	new[76]	_	_
9-8	1405-1418	computational	abstract[76]	new[76]	_	_
9-9	1419-1425	method	abstract[76]	new[76]	_	_
9-10	1426-1430	that	abstract[76]	new[76]	_	_
9-11	1431-1440	leverages	abstract[76]	new[76]	_	_
9-12	1441-1444	the	abstract[76]|abstract[79]	new[76]|new[79]	coref	13-4[118_79]
9-13	1445-1454	available	abstract[76]|abstract[79]	new[76]|new[79]	_	_
9-14	1455-1461	cancer	abstract[76]|abstract|abstract[79]	new[76]|giv|new[79]	coref	9-25
9-15	1462-1469	genetic	abstract[76]|abstract[79]	new[76]|new[79]	_	_
9-16	1470-1474	data	abstract[76]|abstract|abstract[79]	new[76]|giv|new[79]	coref	9-34[85_0]
9-17	1475-1484	resources	abstract[76]|abstract[79]	new[76]|new[79]	_	_
9-18	1485-1487	to	_	_	_	_
9-19	1488-1495	predict	_	_	_	_
9-20	1496-1505	synthetic	person[80]	new[80]	_	_
9-21	1506-1512	lethal	person[80]	new[80]	_	_
9-22	1513-1521	partners	person[80]	new[80]	_	_
9-23	1522-1524	of	person[80]	new[80]	_	_
9-24	1525-1528	all	person[80]|abstract[83]	new[80]|giv[83]	coref	12-15[113_83]
9-25	1529-1535	cancer	person[80]|abstract|abstract[83]	new[80]|giv|giv[83]	coref	10-25
9-26	1536-1550	susceptibility	person[80]|abstract|abstract[83]	new[80]|new|giv[83]	_	_
9-27	1551-1556	genes	person[80]|abstract[83]	new[80]|giv[83]	_	_
9-28	1557-1560	and	_	_	_	_
9-29	1561-1569	assesses	_	_	_	_
9-30	1570-1573	the	abstract[84]	giv[84]	coref	13-16[122_84]
9-31	1574-1582	clinical	abstract[84]	giv[84]	_	_
9-32	1583-1592	relevance	abstract[84]	giv[84]	_	_
9-33	1593-1597	from	_	_	_	_
9-34	1598-1605	matched	abstract[85]	giv[85]	coref	10-19[95_85]
9-35	1606-1614	clinical	abstract[85]	giv[85]	_	_
9-36	1615-1619	data	abstract[85]	giv[85]	_	_
9-37	1620-1621	.	_	_	_	_

#Text=The computational predictions of SL interactions were subjected to extensive in silico validation using either published literature or shRNA and drug screening data from cancer cell lines .
10-1	1622-1625	The	abstract[86]	new[86]	_	_
10-2	1626-1639	computational	abstract[86]	new[86]	_	_
10-3	1640-1651	predictions	abstract[86]	new[86]	_	_
10-4	1652-1654	of	abstract[86]	new[86]	_	_
10-5	1655-1657	SL	abstract[86]|abstract|abstract[88]	new[86]|giv|giv[88]	coref	13-22
10-6	1658-1670	interactions	abstract[86]|abstract[88]	new[86]|giv[88]	_	_
10-7	1671-1675	were	_	_	_	_
10-8	1676-1685	subjected	_	_	_	_
10-9	1686-1688	to	_	_	_	_
10-10	1689-1698	extensive	event[90]	new[90]	_	_
10-11	1699-1701	in	event[90]	new[90]	_	_
10-12	1702-1708	silico	place|event[90]	giv|new[90]	_	_
10-13	1709-1719	validation	event[90]	new[90]	_	_
10-14	1720-1725	using	event[90]	new[90]	_	_
10-15	1726-1732	either	event[90]|abstract[91]	new[90]|new[91]	coref	20-14[0_91]
10-16	1733-1742	published	event[90]|abstract[91]	new[90]|new[91]	_	_
10-17	1743-1753	literature	event[90]|abstract[91]	new[90]|new[91]	_	_
10-18	1754-1756	or	event[90]	new[90]	_	_
10-19	1757-1762	shRNA	event[90]|abstract|abstract[95]	new[90]|new|giv[95]	coref	15-4[141_95]
10-20	1763-1766	and	event[90]|abstract[95]	new[90]|giv[95]	_	_
10-21	1767-1771	drug	event[90]|substance|abstract[95]	new[90]|giv|giv[95]	coref	11-17
10-22	1772-1781	screening	event[90]|event|abstract[95]	new[90]|giv|giv[95]	coref	15-5[140_0]
10-23	1782-1786	data	event[90]|abstract[95]	new[90]|giv[95]	_	_
10-24	1787-1791	from	event[90]|abstract[95]	new[90]|giv[95]	_	_
10-25	1792-1798	cancer	event[90]|abstract[95]|abstract|object[98]	new[90]|giv[95]|giv|giv[98]	coref|coref	12-15|15-13[147_98]
10-26	1799-1803	cell	event[90]|abstract[95]|place|object[98]	new[90]|giv[95]|giv|giv[98]	coref	15-15
10-27	1804-1809	lines	event[90]|abstract[95]|object[98]	new[90]|giv[95]|giv[98]	_	_
10-28	1810-1811	.	_	_	_	_

#Text=SL-BioDP is a comprehensive resource for the query and visualization of cancer-specific synthetic lethality and potential drug targets based on the concept of synthetic lethality .
11-1	1812-1820	SL-BioDP	abstract	giv	coref	11-3[100_0]
11-2	1821-1823	is	_	_	_	_
11-3	1824-1825	a	abstract[100]	giv[100]	coref	13-12[0_100]
11-4	1826-1839	comprehensive	abstract[100]	giv[100]	_	_
11-5	1840-1848	resource	abstract[100]	giv[100]	_	_
11-6	1849-1852	for	abstract[100]	giv[100]	_	_
11-7	1853-1856	the	abstract[100]|abstract[101]	giv[100]|new[101]	_	_
11-8	1857-1862	query	abstract[100]|abstract[101]	giv[100]|new[101]	_	_
11-9	1863-1866	and	abstract[100]	giv[100]	_	_
11-10	1867-1880	visualization	abstract[100]	giv[100]	_	_
11-11	1881-1883	of	abstract[100]	giv[100]	_	_
11-12	1884-1899	cancer-specific	abstract[100]|abstract[102]	giv[100]|giv[102]	coref	11-24[106_102]
11-13	1900-1909	synthetic	abstract[100]|abstract[102]	giv[100]|giv[102]	_	_
11-14	1910-1919	lethality	abstract[100]|abstract[102]	giv[100]|giv[102]	_	_
11-15	1920-1923	and	abstract[100]	giv[100]	_	_
11-16	1924-1933	potential	abstract[100]|abstract[104]	giv[100]|giv[104]	coref	15-18[149_104]
11-17	1934-1938	drug	abstract[100]|substance|abstract[104]	giv[100]|giv|giv[104]	coref	14-4
11-18	1939-1946	targets	abstract[100]|abstract[104]	giv[100]|giv[104]	_	_
11-19	1947-1952	based	abstract[100]|abstract[104]	giv[100]|giv[104]	_	_
11-20	1953-1955	on	abstract[100]|abstract[104]	giv[100]|giv[104]	_	_
11-21	1956-1959	the	abstract[100]|abstract[104]|abstract[105]	giv[100]|giv[104]|new[105]	coref	21-21[214_105]
11-22	1960-1967	concept	abstract[100]|abstract[104]|abstract[105]	giv[100]|giv[104]|new[105]	_	_
11-23	1968-1970	of	abstract[100]|abstract[104]|abstract[105]	giv[100]|giv[104]|new[105]	_	_
11-24	1971-1980	synthetic	abstract[100]|abstract[104]|abstract[105]|abstract[106]	giv[100]|giv[104]|new[105]|giv[106]	coref	13-9[119_106]
11-25	1981-1990	lethality	abstract[100]|abstract[104]|abstract[105]|abstract[106]	giv[100]|giv[104]|new[105]|giv[106]	_	_
11-26	1991-1992	.	_	_	_	_

#Text=The utility of this web tool is that it enables multilevel querying based on cancer genes , tissues , or drugs of interest .
12-1	1993-1996	The	abstract[107]	new[107]	_	_
12-2	1997-2004	utility	abstract[107]	new[107]	_	_
12-3	2005-2007	of	abstract[107]	new[107]	_	_
12-4	2008-2012	this	abstract[107]|abstract[109]	new[107]|new[109]	ana	12-9[0_109]
12-5	2013-2016	web	abstract[107]|abstract|abstract[109]	new[107]|new|new[109]	_	_
12-6	2017-2021	tool	abstract[107]|abstract[109]	new[107]|new[109]	_	_
12-7	2022-2024	is	_	_	_	_
12-8	2025-2029	that	_	_	_	_
12-9	2030-2032	it	abstract	giv	coref	21-8[212_0]
12-10	2033-2040	enables	_	_	_	_
12-11	2041-2051	multilevel	abstract[111]	new[111]	_	_
12-12	2052-2060	querying	abstract[111]	new[111]	_	_
12-13	2061-2066	based	abstract[111]	new[111]	_	_
12-14	2067-2069	on	abstract[111]	new[111]	_	_
12-15	2070-2076	cancer	abstract[111]|abstract|abstract[113]|abstract[114]	new[111]|giv|giv[113]|giv[114]	coref|coref|coref	12-15[114_113]|14-13[134_114]|15-14
12-16	2077-2082	genes	abstract[111]|abstract[113]|abstract[114]	new[111]|giv[113]|giv[114]	_	_
12-17	2083-2084	,	abstract[111]|abstract[114]	new[111]|giv[114]	_	_
12-18	2085-2092	tissues	abstract[111]|abstract[114]|object	new[111]|giv[114]|new	_	_
12-19	2093-2094	,	abstract[111]|abstract[114]	new[111]|giv[114]	_	_
12-20	2095-2097	or	abstract[111]|abstract[114]	new[111]|giv[114]	_	_
12-21	2098-2103	drugs	abstract[111]|abstract[114]|substance[116]	new[111]|giv[114]|new[116]	coref	17-10[170_116]
12-22	2104-2106	of	abstract[111]|abstract[114]|substance[116]	new[111]|giv[114]|new[116]	_	_
12-23	2107-2115	interest	abstract[111]|abstract[114]|substance[116]	new[111]|giv[114]|new[116]	_	_
12-24	2116-2117	.	_	_	_	_

#Text=In contrast to the other database resources on synthetic lethality , SL-BioDP enables assessment of the clinical relevance of targeting the SL interactor gene in the presence of mutation in the primary gene .
13-1	2118-2120	In	_	_	_	_
13-2	2121-2129	contrast	_	_	_	_
13-3	2130-2132	to	_	_	_	_
13-4	2133-2136	the	abstract[118]	giv[118]	_	_
13-5	2137-2142	other	abstract[118]	giv[118]	_	_
13-6	2143-2151	database	abstract|abstract[118]	new|giv[118]	_	_
13-7	2152-2161	resources	abstract[118]	giv[118]	_	_
13-8	2162-2164	on	abstract[118]	giv[118]	_	_
13-9	2165-2174	synthetic	abstract[118]|abstract[119]	giv[118]|giv[119]	coref	21-24[215_119]
13-10	2175-2184	lethality	abstract[118]|abstract[119]	giv[118]|giv[119]	_	_
13-11	2185-2186	,	_	_	_	_
13-12	2187-2195	SL-BioDP	abstract	giv	coref	14-22
13-13	2196-2203	enables	_	_	_	_
13-14	2204-2214	assessment	abstract[121]	new[121]	_	_
13-15	2215-2217	of	abstract[121]	new[121]	_	_
13-16	2218-2221	the	abstract[121]|abstract[122]	new[121]|giv[122]	coref	21-29[216_122]
13-17	2222-2230	clinical	abstract[121]|abstract[122]	new[121]|giv[122]	_	_
13-18	2231-2240	relevance	abstract[121]|abstract[122]	new[121]|giv[122]	_	_
13-19	2241-2243	of	abstract[121]|abstract[122]	new[121]|giv[122]	_	_
13-20	2244-2253	targeting	abstract[121]|abstract[122]	new[121]|giv[122]	_	_
13-21	2254-2257	the	abstract[121]|abstract[122]|abstract[125]	new[121]|giv[122]|new[125]	coref	13-31[128_125]
13-22	2258-2260	SL	abstract[121]|abstract[122]|abstract|abstract[125]	new[121]|giv[122]|giv|new[125]	coref	17-14
13-23	2261-2271	interactor	abstract[121]|abstract[122]|person|abstract[125]	new[121]|giv[122]|new|new[125]	_	_
13-24	2272-2276	gene	abstract[121]|abstract[122]|abstract[125]	new[121]|giv[122]|new[125]	_	_
13-25	2277-2279	in	abstract[121]|abstract[122]	new[121]|giv[122]	_	_
13-26	2280-2283	the	abstract[121]|abstract[122]|abstract[126]	new[121]|giv[122]|new[126]	_	_
13-27	2284-2292	presence	abstract[121]|abstract[122]|abstract[126]	new[121]|giv[122]|new[126]	_	_
13-28	2293-2295	of	abstract[121]|abstract[122]|abstract[126]	new[121]|giv[122]|new[126]	_	_
13-29	2296-2304	mutation	abstract[121]|abstract[122]|abstract[126]|abstract[127]	new[121]|giv[122]|new[126]|new[127]	coref	15-10[0_127]
13-30	2305-2307	in	abstract[121]|abstract[122]|abstract[126]|abstract[127]	new[121]|giv[122]|new[126]|new[127]	_	_
13-31	2308-2311	the	abstract[121]|abstract[122]|abstract[126]|abstract[127]|abstract[128]	new[121]|giv[122]|new[126]|new[127]|giv[128]	coref	15-40[158_128]
13-32	2312-2319	primary	abstract[121]|abstract[122]|abstract[126]|abstract[127]|abstract[128]	new[121]|giv[122]|new[126]|new[127]|giv[128]	_	_
13-33	2320-2324	gene	abstract[121]|abstract[122]|abstract[126]|abstract[127]|abstract[128]	new[121]|giv[122]|new[126]|new[127]|giv[128]	_	_
13-34	2325-2326	.	_	_	_	_

#Text=The prediction of drug response depending on the presence of mutations in the primary genes is another important feature added in SL-BioDP .
14-1	2327-2330	The	abstract[129]	new[129]	coref	14-17[135_129]
14-2	2331-2341	prediction	abstract[129]	new[129]	_	_
14-3	2342-2344	of	abstract[129]	new[129]	_	_
14-4	2345-2349	drug	abstract[129]|substance|event[131]	new[129]|giv|new[131]	coref	15-5
14-5	2350-2358	response	abstract[129]|event[131]	new[129]|new[131]	_	_
14-6	2359-2368	depending	abstract[129]	new[129]	_	_
14-7	2369-2371	on	abstract[129]	new[129]	_	_
14-8	2372-2375	the	abstract[129]|abstract[132]	new[129]|new[132]	_	_
14-9	2376-2384	presence	abstract[129]|abstract[132]	new[129]|new[132]	_	_
14-10	2385-2387	of	abstract[129]|abstract[132]	new[129]|new[132]	_	_
14-11	2388-2397	mutations	abstract[129]|abstract[132]|abstract[133]	new[129]|new[132]|giv[133]	_	_
14-12	2398-2400	in	abstract[129]|abstract[132]|abstract[133]	new[129]|new[132]|giv[133]	_	_
14-13	2401-2404	the	abstract[129]|abstract[132]|abstract[133]|abstract[134]	new[129]|new[132]|giv[133]|giv[134]	_	_
14-14	2405-2412	primary	abstract[129]|abstract[132]|abstract[133]|abstract[134]	new[129]|new[132]|giv[133]|giv[134]	_	_
14-15	2413-2418	genes	abstract[129]|abstract[132]|abstract[133]|abstract[134]	new[129]|new[132]|giv[133]|giv[134]	_	_
14-16	2419-2421	is	_	_	_	_
14-17	2422-2429	another	abstract[135]	giv[135]	_	_
14-18	2430-2439	important	abstract[135]	giv[135]	_	_
14-19	2440-2447	feature	abstract[135]	giv[135]	_	_
14-20	2448-2453	added	abstract[135]	giv[135]	_	_
14-21	2454-2456	in	abstract[135]	giv[135]	_	_
14-22	2457-2465	SL-BioDP	abstract[135]|abstract	giv[135]|giv	coref	19-9
14-23	2466-2467	.	_	_	_	_

#Text=Our analysis of published drug screening data and gene mutation data from matched cancer cell lines identified known synthetic lethality-based drug targets like sensitivity of the drug , olaparib ( PARP inhibitor ) in the presence of mutation in the BRCA1 gene , and in general the homologous recombination repair pathway .
15-1	2468-2471	Our	person|abstract[138]	acc|new[138]	coref|ana	16-4[162_138]|17-1
15-2	2472-2480	analysis	abstract[138]	new[138]	_	_
15-3	2481-2483	of	abstract[138]	new[138]	_	_
15-4	2484-2493	published	abstract[138]|abstract[141]|abstract[142]	new[138]|giv[141]|giv[142]	coref|coref	15-4[142_141]|15-9[144_142]
15-5	2494-2498	drug	abstract[138]|substance|event[140]|abstract[141]|abstract[142]	new[138]|giv|giv[140]|giv[141]|giv[142]	coref	15-21
15-6	2499-2508	screening	abstract[138]|event[140]|abstract[141]|abstract[142]	new[138]|giv[140]|giv[141]|giv[142]	_	_
15-7	2509-2513	data	abstract[138]|abstract[141]|abstract[142]	new[138]|giv[141]|giv[142]	_	_
15-8	2514-2517	and	abstract[138]|abstract[142]	new[138]|giv[142]	_	_
15-9	2518-2522	gene	abstract[138]|abstract[142]|abstract[144]	new[138]|giv[142]|giv[144]	_	_
15-10	2523-2531	mutation	abstract[138]|abstract[142]|abstract|abstract[144]	new[138]|giv[142]|giv|giv[144]	coref	15-38[156_0]
15-11	2532-2536	data	abstract[138]|abstract[142]|abstract[144]	new[138]|giv[142]|giv[144]	_	_
15-12	2537-2541	from	abstract[138]|abstract[142]|abstract[144]	new[138]|giv[142]|giv[144]	_	_
15-13	2542-2549	matched	abstract[138]|abstract[142]|abstract[144]|object[147]	new[138]|giv[142]|giv[144]|giv[147]	_	_
15-14	2550-2556	cancer	abstract[138]|abstract[142]|abstract[144]|abstract|object[147]	new[138]|giv[142]|giv[144]|giv|giv[147]	coref	18-21
15-15	2557-2561	cell	abstract[138]|abstract[142]|abstract[144]|place|object[147]	new[138]|giv[142]|giv[144]|giv|giv[147]	_	_
15-16	2562-2567	lines	abstract[138]|abstract[142]|abstract[144]|object[147]	new[138]|giv[142]|giv[144]|giv[147]	_	_
15-17	2568-2578	identified	_	_	_	_
15-18	2579-2584	known	abstract[149]	giv[149]	_	_
15-19	2585-2594	synthetic	abstract[149]	giv[149]	_	_
15-20	2595-2610	lethality-based	abstract[149]	giv[149]	_	_
15-21	2611-2615	drug	substance|abstract[149]	giv|giv[149]	coref	15-26[151_0]
15-22	2616-2623	targets	abstract[149]	giv[149]	_	_
15-23	2624-2628	like	abstract[149]	giv[149]	_	_
15-24	2629-2640	sensitivity	abstract[149]|abstract[150]	giv[149]|new[150]	_	_
15-25	2641-2643	of	abstract[149]|abstract[150]	giv[149]|new[150]	_	_
15-26	2644-2647	the	abstract[149]|abstract[150]|substance[151]	giv[149]|new[150]|giv[151]	appos	15-29[0_151]
15-27	2648-2652	drug	abstract[149]|abstract[150]|substance[151]	giv[149]|new[150]|giv[151]	_	_
15-28	2653-2654	,	abstract[149]|abstract[150]	giv[149]|new[150]	_	_
15-29	2655-2663	olaparib	abstract[149]|abstract[150]|substance	giv[149]|new[150]|giv	coref	16-15
15-30	2664-2665	(	abstract[149]|abstract[150]	giv[149]|new[150]	_	_
15-31	2666-2670	PARP	abstract[149]|abstract[150]|abstract|abstract[154]	giv[149]|new[150]|new|new[154]	_	_
15-32	2671-2680	inhibitor	abstract[149]|abstract[150]|abstract[154]	giv[149]|new[150]|new[154]	_	_
15-33	2681-2682	)	abstract[149]|abstract[150]	giv[149]|new[150]	_	_
15-34	2683-2685	in	abstract[149]|abstract[150]	giv[149]|new[150]	_	_
15-35	2686-2689	the	abstract[149]|abstract[150]|abstract[155]	giv[149]|new[150]|new[155]	_	_
15-36	2690-2698	presence	abstract[149]|abstract[150]|abstract[155]	giv[149]|new[150]|new[155]	_	_
15-37	2699-2701	of	abstract[149]|abstract[150]|abstract[155]	giv[149]|new[150]|new[155]	_	_
15-38	2702-2710	mutation	abstract[149]|abstract[150]|abstract[155]|abstract[156]	giv[149]|new[150]|new[155]|giv[156]	coref	18-8[175_156]
15-39	2711-2713	in	abstract[149]|abstract[150]|abstract[155]|abstract[156]	giv[149]|new[150]|new[155]|giv[156]	_	_
15-40	2714-2717	the	abstract[149]|abstract[150]|abstract[155]|abstract[156]|abstract[158]	giv[149]|new[150]|new[155]|giv[156]|giv[158]	coref	16-13[0_158]
15-41	2718-2723	BRCA1	abstract[149]|abstract[150]|abstract[155]|abstract[156]|abstract|abstract[158]	giv[149]|new[150]|new[155]|giv[156]|new|giv[158]	_	_
15-42	2724-2728	gene	abstract[149]|abstract[150]|abstract[155]|abstract[156]|abstract[158]	giv[149]|new[150]|new[155]|giv[156]|giv[158]	_	_
15-43	2729-2730	,	abstract[149]	giv[149]	_	_
15-44	2731-2734	and	abstract[149]	giv[149]	_	_
15-45	2735-2737	in	abstract[149]	giv[149]	_	_
15-46	2738-2745	general	abstract[149]|abstract[161]	giv[149]|new[161]	_	_
15-47	2746-2749	the	abstract[149]|abstract[161]	giv[149]|new[161]	_	_
15-48	2750-2760	homologous	abstract[149]|event[159]|abstract[160]|abstract[161]	giv[149]|new[159]|new[160]|new[161]	_	_
15-49	2761-2774	recombination	abstract[149]|event[159]|abstract[160]|abstract[161]	giv[149]|new[159]|new[160]|new[161]	_	_
15-50	2775-2781	repair	abstract[149]|abstract[160]|abstract[161]	giv[149]|new[160]|new[161]	_	_
15-51	2782-2789	pathway	abstract[149]|abstract[161]	giv[149]|new[161]	_	_
15-52	2790-2791	.	_	_	_	_

#Text=In addition , the analysis offers to look into new potentially effective gene mutation-based drug therapies .
16-1	2792-2794	In	_	_	_	_
16-2	2795-2803	addition	_	_	_	_
16-3	2804-2805	,	_	_	_	_
16-4	2806-2809	the	abstract[162]	giv[162]	coref	17-3[168_162]
16-5	2810-2818	analysis	abstract[162]	giv[162]	_	_
16-6	2819-2825	offers	_	_	_	_
16-7	2826-2828	to	_	_	_	_
16-8	2829-2833	look	_	_	_	_
16-9	2834-2838	into	_	_	_	_
16-10	2839-2842	new	abstract[165]	new[165]	coref	21-14[213_165]
16-11	2843-2854	potentially	abstract[165]	new[165]	_	_
16-12	2855-2864	effective	abstract[165]	new[165]	_	_
16-13	2865-2869	gene	abstract|abstract[165]	giv|new[165]	coref	18-17[178_0]
16-14	2870-2884	mutation-based	abstract[165]	new[165]	_	_
16-15	2885-2889	drug	substance|abstract[165]	giv|new[165]	coref	19-3
16-16	2890-2899	therapies	abstract[165]	new[165]	_	_
16-17	2900-2901	.	_	_	_	_

#Text=We extended our analysis to infer potential synergy between drugs targeting the predicted SL interactors .
17-1	2902-2904	We	person	giv	ana	17-3
17-2	2905-2913	extended	_	_	_	_
17-3	2914-2917	our	person|abstract[168]	giv|giv[168]	ana	18-1
17-4	2918-2926	analysis	abstract[168]	giv[168]	_	_
17-5	2927-2929	to	_	_	_	_
17-6	2930-2935	infer	_	_	_	_
17-7	2936-2945	potential	abstract[169]	new[169]	_	_
17-8	2946-2953	synergy	abstract[169]	new[169]	_	_
17-9	2954-2961	between	abstract[169]	new[169]	_	_
17-10	2962-2967	drugs	abstract[169]|substance[170]	new[169]|giv[170]	coref	18-25[181_170]
17-11	2968-2977	targeting	abstract[169]|substance[170]	new[169]|giv[170]	_	_
17-12	2978-2981	the	abstract[169]|substance[170]|event[172]	new[169]|giv[170]|giv[172]	_	_
17-13	2982-2991	predicted	abstract[169]|substance[170]|event[172]	new[169]|giv[170]|giv[172]	_	_
17-14	2992-2994	SL	abstract[169]|substance[170]|abstract|event[172]	new[169]|giv[170]|giv|giv[172]	coref	18-29
17-15	2995-3006	interactors	abstract[169]|substance[170]|event[172]	new[169]|giv[170]|giv[172]	_	_
17-16	3007-3008	.	_	_	_	_

#Text=We reasoned that if the presence of a mutation ( or loss of function ) in a primary gene makes cancer cells sensitive to certain drugs targeting an SL interactor , then it is highly likely that the drugs targeting the primary gene will also make the cancer cells sensitive to those drugs targeting the SL interactor .
18-1	3009-3011	We	person	giv	ana	20-4
18-2	3012-3020	reasoned	_	_	_	_
18-3	3021-3025	that	_	_	_	_
18-4	3026-3028	if	_	_	_	_
18-5	3029-3032	the	abstract[174]	new[174]	_	_
18-6	3033-3041	presence	abstract[174]	new[174]	_	_
18-7	3042-3044	of	abstract[174]	new[174]	_	_
18-8	3045-3046	a	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
18-9	3047-3055	mutation	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
18-10	3056-3057	(	abstract[174]	new[174]	_	_
18-11	3058-3060	or	abstract[174]	new[174]	_	_
18-12	3061-3065	loss	abstract[174]|event[176]	new[174]|new[176]	_	_
18-13	3066-3068	of	abstract[174]|event[176]	new[174]|new[176]	_	_
18-14	3069-3077	function	abstract[174]|event[176]|abstract	new[174]|new[176]|new	_	_
18-15	3078-3079	)	abstract[174]|event[176]	new[174]|new[176]	_	_
18-16	3080-3082	in	abstract[174]|event[176]	new[174]|new[176]	_	_
18-17	3083-3084	a	abstract[174]|event[176]|abstract[178]	new[174]|new[176]|giv[178]	coref	18-41[186_178]
18-18	3085-3092	primary	abstract[174]|event[176]|abstract[178]	new[174]|new[176]|giv[178]	_	_
18-19	3093-3097	gene	abstract[174]|event[176]|abstract[178]	new[174]|new[176]|giv[178]	_	_
18-20	3098-3103	makes	_	_	_	_
18-21	3104-3110	cancer	abstract|animal[180]	giv|giv[180]	coref|coref	18-48|18-47[188_180]
18-22	3111-3116	cells	animal[180]	giv[180]	_	_
18-23	3117-3126	sensitive	_	_	_	_
18-24	3127-3129	to	_	_	_	_
18-25	3130-3137	certain	substance[181]	giv[181]	coref	18-38[185_181]
18-26	3138-3143	drugs	substance[181]	giv[181]	_	_
18-27	3144-3153	targeting	substance[181]	giv[181]	_	_
18-28	3154-3156	an	substance[181]|abstract[183]	giv[181]|new[183]	ana	18-33[0_183]
18-29	3157-3159	SL	substance[181]|abstract|abstract[183]	giv[181]|giv|new[183]	coref	18-56
18-30	3160-3170	interactor	substance[181]|abstract[183]	giv[181]|new[183]	_	_
18-31	3171-3172	,	_	_	_	_
18-32	3173-3177	then	_	_	_	_
18-33	3178-3180	it	abstract	giv	coref	18-55[191_0]
18-34	3181-3183	is	_	_	_	_
18-35	3184-3190	highly	_	_	_	_
18-36	3191-3197	likely	_	_	_	_
18-37	3198-3202	that	_	_	_	_
18-38	3203-3206	the	substance[185]	giv[185]	coref	18-52[189_185]
18-39	3207-3212	drugs	substance[185]	giv[185]	_	_
18-40	3213-3222	targeting	substance[185]	giv[185]	_	_
18-41	3223-3226	the	substance[185]|abstract[186]	giv[185]|giv[186]	_	_
18-42	3227-3234	primary	substance[185]|abstract[186]	giv[185]|giv[186]	_	_
18-43	3235-3239	gene	substance[185]|abstract[186]	giv[185]|giv[186]	_	_
18-44	3240-3244	will	_	_	_	_
18-45	3245-3249	also	_	_	_	_
18-46	3250-3254	make	_	_	_	_
18-47	3255-3258	the	animal[188]	giv[188]	_	_
18-48	3259-3265	cancer	abstract|animal[188]	giv|giv[188]	_	_
18-49	3266-3271	cells	animal[188]	giv[188]	_	_
18-50	3272-3281	sensitive	_	_	_	_
18-51	3282-3284	to	_	_	_	_
18-52	3285-3290	those	substance[189]	giv[189]	coref	20-7[201_189]
18-53	3291-3296	drugs	substance[189]	giv[189]	_	_
18-54	3297-3306	targeting	substance[189]	giv[189]	_	_
18-55	3307-3310	the	substance[189]|abstract[191]	giv[189]|giv[191]	_	_
18-56	3311-3313	SL	substance[189]|abstract|abstract[191]	giv[189]|giv|giv[191]	_	_
18-57	3314-3324	interactor	substance[189]|abstract[191]	giv[189]|giv[191]	_	_
18-58	3325-3326	.	_	_	_	_

#Text=These inferred drug synergies can be searched in SL-BioDP for each of the 18 tumor histologies included in SL-BioDP .
19-1	3327-3332	These	abstract[193]	new[193]	_	_
19-2	3333-3341	inferred	abstract[193]	new[193]	_	_
19-3	3342-3346	drug	substance|abstract[193]	giv|new[193]	_	_
19-4	3347-3356	synergies	abstract[193]	new[193]	_	_
19-5	3357-3360	can	_	_	_	_
19-6	3361-3363	be	_	_	_	_
19-7	3364-3372	searched	_	_	_	_
19-8	3373-3375	in	_	_	_	_
19-9	3376-3384	SL-BioDP	abstract	giv	coref	19-19
19-10	3385-3388	for	_	_	_	_
19-11	3389-3393	each	_	_	_	_
19-12	3394-3396	of	_	_	_	_
19-13	3397-3400	the	abstract[196]	new[196]	_	_
19-14	3401-3403	18	abstract[196]	new[196]	_	_
19-15	3404-3409	tumor	abstract|abstract[196]	giv|new[196]	_	_
19-16	3410-3421	histologies	abstract[196]	new[196]	_	_
19-17	3422-3430	included	abstract[196]	new[196]	_	_
19-18	3431-3433	in	abstract[196]	new[196]	_	_
19-19	3434-3442	SL-BioDP	abstract[196]|abstract	new[196]|giv	coref	21-4
19-20	3443-3444	.	_	_	_	_

#Text=In support of our predictions of synergistic drugs in cancers , we collected literature references and reports of ongoing clinical trials , which is included in Supplementary Table S3 .
20-1	3445-3447	In	_	_	_	_
20-2	3448-3455	support	abstract[198]	new[198]	_	_
20-3	3456-3458	of	abstract[198]	new[198]	_	_
20-4	3459-3462	our	abstract[198]|person|abstract[200]	new[198]|giv|new[200]	ana	20-12
20-5	3463-3474	predictions	abstract[198]|abstract[200]	new[198]|new[200]	_	_
20-6	3475-3477	of	abstract[198]|abstract[200]	new[198]|new[200]	_	_
20-7	3478-3489	synergistic	abstract[198]|abstract[200]|substance[201]	new[198]|new[200]|giv[201]	_	_
20-8	3490-3495	drugs	abstract[198]|abstract[200]|substance[201]	new[198]|new[200]|giv[201]	_	_
20-9	3496-3498	in	abstract[198]|abstract[200]|substance[201]	new[198]|new[200]|giv[201]	_	_
20-10	3499-3506	cancers	abstract[198]|abstract[200]|substance[201]|abstract	new[198]|new[200]|giv[201]|giv	_	_
20-11	3507-3508	,	_	_	_	_
20-12	3509-3511	we	person	giv	_	_
20-13	3512-3521	collected	_	_	_	_
20-14	3522-3532	literature	abstract|abstract[205]	giv|new[205]	_	_
20-15	3533-3543	references	abstract[205]	new[205]	_	_
20-16	3544-3547	and	_	_	_	_
20-17	3548-3555	reports	abstract[206]	new[206]	_	_
20-18	3556-3558	of	abstract[206]	new[206]	_	_
20-19	3559-3566	ongoing	abstract[206]|event[207]	new[206]|new[207]	_	_
20-20	3567-3575	clinical	abstract[206]|event[207]	new[206]|new[207]	_	_
20-21	3576-3582	trials	abstract[206]|event[207]	new[206]|new[207]	_	_
20-22	3583-3584	,	abstract[206]	new[206]	_	_
20-23	3585-3590	which	abstract[206]	new[206]	_	_
20-24	3591-3593	is	abstract[206]	new[206]	_	_
20-25	3594-3602	included	abstract[206]	new[206]	_	_
20-26	3603-3605	in	abstract[206]	new[206]	_	_
20-27	3606-3619	Supplementary	abstract[206]|object|abstract[209]	new[206]|new|new[209]	_	_
20-28	3620-3625	Table	abstract[206]|abstract[209]	new[206]|new[209]	_	_
20-29	3626-3628	S3	abstract	new	_	_
20-30	3629-3630	.	_	_	_	_

#Text=Combined together , SL-BioDP can serve as a comprehensive tool , for exploring potentially actionable mutation-based targeted therapies based on the concept of synthetic lethality , that shows possible clinical relevance .
21-1	3631-3639	Combined	_	_	_	_
21-2	3640-3648	together	_	_	_	_
21-3	3649-3650	,	_	_	_	_
21-4	3651-3659	SL-BioDP	abstract	giv	_	_
21-5	3660-3663	can	_	_	_	_
21-6	3664-3669	serve	_	_	_	_
21-7	3670-3672	as	_	_	_	_
21-8	3673-3674	a	abstract[212]	giv[212]	_	_
21-9	3675-3688	comprehensive	abstract[212]	giv[212]	_	_
21-10	3689-3693	tool	abstract[212]	giv[212]	_	_
21-11	3694-3695	,	_	_	_	_
21-12	3696-3699	for	_	_	_	_
21-13	3700-3709	exploring	_	_	_	_
21-14	3710-3721	potentially	abstract[213]	giv[213]	_	_
21-15	3722-3732	actionable	abstract[213]	giv[213]	_	_
21-16	3733-3747	mutation-based	abstract[213]	giv[213]	_	_
21-17	3748-3756	targeted	abstract[213]	giv[213]	_	_
21-18	3757-3766	therapies	abstract[213]	giv[213]	_	_
21-19	3767-3772	based	abstract[213]	giv[213]	_	_
21-20	3773-3775	on	abstract[213]	giv[213]	_	_
21-21	3776-3779	the	abstract[213]|abstract[214]	giv[213]|giv[214]	_	_
21-22	3780-3787	concept	abstract[213]|abstract[214]	giv[213]|giv[214]	_	_
21-23	3788-3790	of	abstract[213]|abstract[214]	giv[213]|giv[214]	_	_
21-24	3791-3800	synthetic	abstract[213]|abstract[214]|abstract[215]	giv[213]|giv[214]|giv[215]	_	_
21-25	3801-3810	lethality	abstract[213]|abstract[214]|abstract[215]	giv[213]|giv[214]|giv[215]	_	_
21-26	3811-3812	,	abstract[213]	giv[213]	_	_
21-27	3813-3817	that	abstract[213]	giv[213]	_	_
21-28	3818-3823	shows	abstract[213]	giv[213]	_	_
21-29	3824-3832	possible	abstract[213]|abstract[216]	giv[213]|giv[216]	_	_
21-30	3833-3841	clinical	abstract[213]|abstract[216]	giv[213]|giv[216]	_	_
21-31	3842-3851	relevance	abstract[213]|abstract[216]	giv[213]|giv[216]	_	_
21-32	3852-3853	.	_	_	_	_
